Lineage Cell Therapeutics Inc. has reported its financial and operating results for the first quarter of 2025. The company, which specializes in developing novel allogeneic cell therapies for serious neurological and ophthalmic conditions, recorded total revenues of $1.5 million during this period, marking an increase of $0.1 million compared to $1.4 million in the first quarter of 2024. This rise was primarily attributed to increased collaboration revenue recognized from deferred revenues under its agreement with Roche. The net loss attributable to Lineage for the three months ended March 31, 2025, was $4.1 million, or $0.02 per share, compared to a net loss of $6.5 million, or $0.04 per share, for the same period in the previous year. Operating expenses for the first quarter of 2025 were reported at $8.0 million, reflecting a slight decrease from $8.1 million in the first quarter of 2024. Research and development expenses saw an increase, reaching $3.1 million compared to $3.0 million in the prior year period. Lineage has expressed growing confidence in its OpRegen treatment's potential to address significant medical needs, with its treatment effects lasting up to 24 months. The company anticipates a 36-month data update from partners Roche and Genentech, which is expected next month. Additionally, recent independent first-in-human results reported by competitors have further validated the RPE transplant mechanism of action, suggesting functional improvements beyond the reach of currently approved dry AMD therapies.